Frontier Pharma: Hematological Cancers - Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific Therapies

Published: June 2016
No. of Pages: 73
    ReportsandReports

Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow, and include numerous forms of leukemia, lymphoma and myeloma.

Hematological malignancies constituted 9% of all newly diagnosed malignancies in the US in 2011, with data indicating that lymphomas are more prevalent than leukemia or myeloma. Excluding acute lymphocytic leukemia and Hodgkin’s lymphoma, these types of malignancy are generally associated with increasing age. Therefore, considering the aging population globally, this class of malignancy is likely to become more prevalent.

The report assesses first-in-class innovation in the hematological cancer pipeline, highlighting key trends in first-in-class product distribution. Analysis reveals that the hematological cancer pipeline is among the most innovative in the industry, with 463 first-in-class products, representing 45.3% of the pipeline with a disclosed molecular target.

The first-in-class targets in the pipeline are numerous and varied in nature. Cancer immunotherapies are the most common, with a total of 128 across all stages of development, followed by the signal transduction group of targets. The most commercially successful targeted drugs in the market fall into these two categories, including Rituxan (a cancer immunotherapy) and Gleevec (a signal transducer). The other target families have much fewer first-in-class products, reflecting the strong interest in cancer immunotherapies and targets implicated in signal transduction.

Over the past 15 years, the treatment of hematological malignancies has changed significantly, with the development of targeted therapies. These developments have been based on the growing understanding of the signaling pathways involved in disease pathogenesis. A notable example is the approval of Rituxan in 1997, which is used to treat multiple types of hematological malignancies, including Non-Hodgkin’s lymphoma. Analysis indicates that the current pipeline is following this trend of focusing on innovative, targeted therapies.

Scope

The hematological cancers market is characterized by commercially successful therapies.

  • Which classes of drug dominate the market?
  • What additional benefits have newly approved therapies brought to the market?
  • The pipeline contains a range of molecule types and molecular targets, with a strong emphasis on targeted therapies, as opposed to chemotherapeutic agents.
  • Which molecular targets appear most frequently in the pipeline?
  • To what degree is the pipeline penetrated by first-in-class innovation?
  • Which target families have the most first-in-class products?

First-in-class products differ substantially in their clinical potential, based on their alignment to disease-causing pathways.

  • How well are first-in-class targets aligned to known disease-causing pathways?
  • Which targets are specifically found in early-stage development?
  • Which are the most promising first-in-class targets in early-stage development?
  • There have been 284 licensing deals and 238 co-development deals pertaining to hematological cancer products since 2006.
  • Which territories show the most deal activity?
  • What were the trends in deal completion by product stage of development?
  • Which of the first-in-class products in development are not currently involved in a licensing or co-development deal, and therefore represent investment opportunities?

Reasons to buy

This report will allow you to -

  • Understand the current clinical and commercial landscape. It includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
  • Visualize the composition of the hematological cancers market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
  • Analyze the hematological cancers pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating hematological cancers.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
  • Identify commercial opportunities in the hematological cancers deals landscape by analyzing trends in licensing and co-development deals and producing a curated list of hematological cancer therapies that are not yet involved in deals, and may be potential investment opportunities.

Published By: GBI Research
Product Code: GBI Research1560


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Related Reports:

  • Global Active Pharmaceutical Ingredient Market by Manufacturers, Regions, Type and Application, Forecast to 2021

    Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs. The active ingredient (AI) is the substance or substances that are biologically active within the drug and is the specific component r...

  • Global Epilepsy Drugs Sales Market Report 2016

    Notes: Sales, means the sales volume of Epilepsy Drugs Revenue, means the sales value of Epilepsy Drugs This report studies sales (consumption) of Epilepsy Drugs in Global market, especially in United States, China, Europe, Japan, focuses on top...

  • Europe Ganciclovir Market Report 2016

    Notes: Sales, means the sales volume of Ganciclovir Revenue, means the sales value of Ganciclovir This report studies sales (consumption) of Ganciclovir in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focus...

  • Europe Typhoid Vaccine Market Report 2016

    Notes: Sales, means the sales volume of Typhoid Vaccine Revenue, means the sales value of Typhoid Vaccine This report studies sales (consumption) of Typhoid Vaccine in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and ...

  • Europe Trastuzumab Market Report 2016

    Notes: Sales, means the sales volume of Trastuzumab Revenue, means the sales value of Trastuzumab This report studies sales (consumption) of Trastuzumab in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focus...

  • Europe Thromboxane A2 Receptor Antagonist Market Report 2016

    Notes: Sales, means the sales volume of Thromboxane A2 Receptor Antagonist Revenue, means the sales value of Thromboxane A2 Receptor Antagonist This report studies sales (consumption) of Thromboxane A2 Receptor Antagonist in Europe market, espec...

  • Europe Salagen Market Report 2016

    Notes: Sales, means the sales volume of Salagen Revenue, means the sales value of Salagen This report studies sales (consumption) of Salagen in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top pl...

  • Europe Rituxan Market Report 2016

    Notes: Sales, means the sales volume of Rituxan Revenue, means the sales value of Rituxan This report studies sales (consumption) of Rituxan in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top pl...

  • Europe Prednisolone Market Report 2016

    Notes: Sales, means the sales volume of Prednisolone Revenue, means the sales value of Prednisolone This report studies sales (consumption) of Prednisolone in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, fo...

  • Europe Pilocarpine Hydrochloride Market Report 2016

    Notes: Sales, means the sales volume of Pilocarpine Hydrochloride Revenue, means the sales value of Pilocarpine Hydrochloride This report studies sales (consumption) of Pilocarpine Hydrochloride in Europe market, especially in Germany, UK, Franc...


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest: